Literature DB >> 15622533

Natural history of neurofibromatosis 1-associated optic nerve glioma in mice.

M Livia Bajenaru1, Joel R Garbow, Arie Perry, M Rosario Hernandez, David H Gutmann.   

Abstract

Children affected with the inherited tumor predisposition syndrome, neurofibromatosis 1 (NF1), are prone to the development of low-grade astrocytic optic pathway tumors (optic pathway glioma [OPG]). Previously, we developed a model of NF1-associated astrocytoma (GFAPCre; Nf1(flox/mut) mice) in which mice develop optic nerve and chiasm glioma. To define the molecular pathogenesis of OPG, we used this mouse model to study the natural history of OPG formation using immunohistological and radiographic approaches. We observed that whereas astrocyte hyperplasia is present in the optic nerves associated with gross optic nerve thickening at 3 weeks of age, overt neoplastic changes were not seen until 2 months of age. Astrocyte proliferation was maximal between 3 weeks and 2 months of age, suggesting that the most rapid period of growth occurs early. Mouse OPG tumors were detected by magnetic resonance imaging at 2 months of age and exhibited contrast enhancement, as seen in human OPG. In addition, the mouse OPG tumors exhibited expression of proteins associated with astroglial progenitors, including nestin and brain lipid binding protein. Last, we observed neovascularization and microglial cell infiltration by 3 weeks of age before overt neoplastic transformation, suggesting that these cellular changes participate in the early stages of tumor formation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15622533     DOI: 10.1002/ana.20337

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  26 in total

1.  NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.

Authors:  Joseph A Toonen; Corina Anastasaki; Laura J Smithson; Scott M Gianino; Kairong Li; Robert A Kesterson; David H Gutmann
Journal:  Hum Mol Genet       Date:  2016-02-16       Impact factor: 6.150

2.  An 80-year experience with optic nerve glioma cases at the Armed Forces Institute of Pathology: evolution from museum to molecular evaluation suggests possibe interventions in the cellular senescence and microglial pathways (an American Ophthalmological Society thesis).

Authors:  J Douglas Cameron; Fausto J Rodriguez; Elisabeth Rushing; Iren Horkayne-Szakaly; Charles Eberhart
Journal:  Trans Am Ophthalmol Soc       Date:  2014

Review 3.  The role of microglia and macrophages in glioma maintenance and progression.

Authors:  Dolores Hambardzumyan; David H Gutmann; Helmut Kettenmann
Journal:  Nat Neurosci       Date:  2016-01       Impact factor: 24.884

4.  Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.

Authors:  Aparna Kaul; Joseph A Toonen; Patrick J Cimino; Scott M Gianino; David H Gutmann
Journal:  Neuro Oncol       Date:  2014-12-21       Impact factor: 12.300

5.  Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivo.

Authors:  Debasish Banerjee; Balazs Hegedus; David H Gutmann; Joel R Garbow
Journal:  Neuroimage       Date:  2007-02-23       Impact factor: 6.556

6.  Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.

Authors:  Grant W Simmons; Winnie W Pong; Ryan J Emnett; Crystal R White; Scott M Gianino; Fausto J Rodriguez; David H Gutmann
Journal:  J Neuropathol Exp Neurol       Date:  2011-01       Impact factor: 3.685

7.  Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.

Authors:  Sutapa Banerjee; Scott M Gianino; Feng Gao; Uwe Christians; David H Gutmann
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

8.  Diffusion-weighted and dynamic contrast-enhanced imaging as markers of clinical behavior in children with optic pathway glioma.

Authors:  Sarah C Jost; Joseph W Ackerman; Joel R Garbow; Linda P Manwaring; David H Gutmann; Robert C McKinstry
Journal:  Pediatr Radiol       Date:  2008-10-10

Review 9.  Pathological and molecular advances in pediatric low-grade astrocytoma.

Authors:  Fausto J Rodriguez; Kah Suan Lim; Daniel Bowers; Charles G Eberhart
Journal:  Annu Rev Pathol       Date:  2012-10-29       Impact factor: 23.472

Review 10.  Genetically engineered mouse models of brain cancer and the promise of preclinical testing.

Authors:  Jason T Huse; Eric C Holland
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.